Anxiety Treatment Guidelines

Introduction to Anxiety Treatment

The American College of Cardiology is not relevant here, however, the evidence strongly supports that first-line treatment should be cognitive behavioral therapy (CBT) combined with—or instead of—medication, as CBT addresses the root psychological patterns while SSRIs/SNRIs require 6-12 weeks for full effect and carry significant side effects 1

Patients often seek immediate relief from anxiety symptoms, but SSRIs follow a logarithmic response pattern with statistically significant improvement beginning at week 2, clinically meaningful improvement by week 6, and maximal benefit not achieved until week 12 or later 1
The most effective approach for anxiety caused by life stressors combines an SSRI (escitalopram or sertraline) with individual CBT, started simultaneously rather than sequentially 1
Start with escitalopram (5-10 mg daily) or sertraline (25-50 mg daily) as first-line SSRIs due to favorable side effect profiles and lower discontinuation syndrome risk 1
Titrate escitalopram by 5-10 mg increments every 1-2 weeks to target 10-20 mg daily 1
Titrate sertraline by 25-50 mg increments every 1-2 weeks to target 50-200 mg daily 1
Begin with lower doses to minimize initial anxiety/agitation that paradoxically occurs with SSRIs 1
Assess for suicidal thoughts and behaviors, especially during the first 1-2 months and following dose adjustments, with pooled risk of 1% versus 0.2% for placebo 1

Refer for individual CBT (12-20 sessions over 3-4 months) targeting anxiety-specific cognitive distortions and avoidance behaviors 1
Individual CBT is prioritized over group therapy due to superior clinical and cost-effectiveness 1
CBT should include psychoeducation, cognitive restructuring, relaxation techniques, and gradual exposure when appropriate 1

Regular cardiovascular exercise provides moderate to large reductions in anxiety symptoms 1
Breathing techniques, progressive muscle relaxation, grounding strategies, and mindfulness serve as useful adjunctive interventions 1
Psychoeducation for family members about anxiety symptoms improves treatment adherence and outcomes 1

Tricyclic antidepressants should be avoided due to unfavorable risk-benefit profile, particularly cardiac toxicity 1
Beta blockers (atenolol, propranolol) are deprecated for anxiety disorders based on negative evidence 3
Paroxetine carries higher risk of discontinuation syndrome and potentially increased suicidal thinking compared to other SSRIs 1

Do not switch medication classes before allowing adequate trial duration (8-12 weeks at therapeutic dose), as this leads to missed opportunities for response 2
Venlafaxine requires blood pressure monitoring due to risk of sustained hypertension 1